跳至主要内容
临床试验/NCT03891095
NCT03891095已完成不适用

Oxytocin and Dopamine's Effect on Vicarious Optimism

Beijing Normal University1 个研究点 分布在 1 个国家目标入组 156 人开始时间: 2018年12月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
156
试验地点
1
主要终点
Belief update value for self, friend and stranger

研究概览

简要总结

To investigate the effect of intranasal Oxytocin and L-DOPA's effect on vicarious optimism.

详细描述

The current study adopted a double-blind, double-dummy, placebo-controlled mixed design, with Treatment (oxytocin, dopamine, and placebo) as a between-subjects factor, and Target (self, friend, and an identifiable stranger) and Feedback (desirable vs. undesirable) as within-subjects factors. Upon arrival, participants first completed a set of questionnaires, including mood measurements and other questionnaires related to optimistic or prosocial tendency. Participants then self-administered with the pharmacological challenge 40 min before the main task, i.e., the belief updating task where participants indicated and updated their beliefs about the future of oneself, a gender-matched best friend, and a gender-matched identifiable stranger. At the end, participants completed the mood measurement again, as well the debriefing questionnaires which designed to measure their beliefs about the experimental process.

For the vicarious optimism task, participants completed three blocks of the two-session belief updating task where they were asked to estimate the likelihood of adverse life events happening to three targets: themselves (referred as Self), a gender-matched best friend (referred as Friend), and an identifiable stranger (whose name, brief description and picture were presented to the participants to get familiar with before the estimation, such as "The stranger is Zhexing, a 25-year-old male, Chinese"; referred as Stranger).

Participants completed two estimation sessions for one target before beginning with the next target, and the order of targets was counterbalanced across participants within each group. For the first session of each target block, participants were first presented with 30 different adverse life events (in a random order) and estimated the likelihood of each event happening to the target in the future (the 1st estimation, referred to as E1) on a self-paced basis. Participants were then presented with the probability of each event occurring to an average person in a similar environment (Feedback) for 2s. In the second session, participants estimated the likelihood of the same 30 events (in a random order) happening to the target person again without receiving feedback (the 2nd estimation, referred to as E2).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

性别
Male
接受健康志愿者

入选标准

  • healthy subjects without past or current psychiatric or neurological disorders

排除标准

  • subjects with past or current psychiatric or neurological disorders

研究组 & 干预措施

Intranasal oxytocin

Experimental

Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland)

干预措施: Oxytocin (Drug)

Intranasal oxytocin

Experimental

Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland)

干预措施: Placebos (Drug)

L-DOPA

Experimental

L-DOPA, a neuropeptide who is a key modulator of complex socioaffective responses including reward, social decision making, learning. Subjects receiving 187.5 mg Madopar (L-DOPA treatment, including 150 mg L-3,4-dihydroxyphenylalanine, together with 37.5 mg benserazide, which promotes higher levels of dopamine in the brain while minimizing side effects from peripheral dopamine)

干预措施: L-DOPA (Drug)

L-DOPA

Experimental

L-DOPA, a neuropeptide who is a key modulator of complex socioaffective responses including reward, social decision making, learning. Subjects receiving 187.5 mg Madopar (L-DOPA treatment, including 150 mg L-3,4-dihydroxyphenylalanine, together with 37.5 mg benserazide, which promotes higher levels of dopamine in the brain while minimizing side effects from peripheral dopamine)

干预措施: Placebos (Drug)

Placebo

Placebo Comparator

Participants in the Placebo group received spray and oral placebos. 24 IU saline (spray placebo) 187.5 mg calcium carbonate (oral placebo)

干预措施: Placebos (Drug)

结局指标

主要结局

Belief update value for self, friend and stranger

时间窗: 40~70 minutes after drug administration

In the vicarious optimistic bias task, participants would make first estimation about the happening likelihood for each event for themselves, friend, and stranger and then receive feedback about the general likelihood of each event happened in future. After all events first estimation, participants would estimate all the event again. So, for the belief update, we used the second estimation value to minus the first estimation value to get the update value, as well as calculating the update value in desirable condition (first estimation \< feedback) and undesirable condition (first estimation \< feedback). Then investigated the general belief updating (gBU) and optimistic belief updating (using desirableBU-undesirableBU) for the three target (self vs. friend vs. stranger) in three treatment groups (Oxytocin vs. L-DOPA vs. Placebo)

次要结局

未报告次要终点

研究者

发起方
Beijing Normal University
申办方类型
Other
责任方
Principal Investigator
主要研究者

ma, yina

Principal Investigator

Beijing Normal University

研究点 (1)

Loading locations...

相似试验